Newly Diagnosed PatientsOlder PatientsAE & ComorbiditiesPerinatal CareTrans HealthAntiretroviral TherapyQuiz Yourself: What Do You Know About Long-Acting Cabotegravir/Rilpivirine?Brian R. Wood, M.D.QuizLong-acting, intramuscular CAB/RPV is an excellent option for maintenance ART. Test your knowledge about the latest research and guidance on this regimen. Providing Quality HIV CareResearch Roundup: HIV Treatment Concerns Specific to WomenSusan Yox, RN, Ed.D.News1 Min ReadCisgender women living with HIV often have different clinical care needs from other patients, making it critical for providers to stay up to date on the latest research focusing specifically on women. All CoverageProviding Quality HIV CareResearch Roundup: Women and HIVSusan Yox, RN, Ed.D.SlideshowWe summarize several recently published studies that, together, offer new insights into practical guidance for HIV clinical care. Providing Quality HIV CareResearch Roundup: Women and HIVSusan Yox, RN, Ed.D.SlideshowWe summarize several recently published studies that, together, offer new insights into practical guidance for HIV clinical care. Providing Quality HIV CareHow Will HIV Care Evolve in 2025?Myles HelfandPodcastYou can't truly look to the future without taking time to make sense of the past. Providing Quality HIV CareHow Will HIV Care Evolve in 2025?Myles HelfandPodcastYou can't truly look to the future without taking time to make sense of the past. Providing Quality HIV CareFrom Provider Stigma to Chemsex: HIV Glasgow 2024 HighlightsRoger PebodyNews6 Min ReadA small HIV science meeting that punches above its weight, the once-every-two-years conference is stuffed with notable clinical developments. Providing Quality HIV CareFrom Provider Stigma to Chemsex: HIV Glasgow 2024 HighlightsRoger PebodyNews6 Min ReadA small HIV science meeting that punches above its weight, the once-every-two-years conference is stuffed with notable clinical developments. HIV Care ContinuumSubstance Use and Sustained Viral Suppression in HIVBarbara JungwirthNews2 Min ReadA large study reinforces the impact of substance use disorders on viral load in people with HIV who are taking antiretroviral therapy. HIV Care ContinuumSubstance Use and Sustained Viral Suppression in HIVBarbara JungwirthNews2 Min ReadA large study reinforces the impact of substance use disorders on viral load in people with HIV who are taking antiretroviral therapy. Antiretroviral TherapyLong-Acting Injectable ART Effective in People With High BMIBarbara JungwirthNews2 Min ReadIn this real-world study, researchers concluded that high BMI need not be an automatic disqualifier for people who would otherwise consider LA-CAB/RPV. Antiretroviral TherapyLong-Acting Injectable ART Effective in People With High BMIBarbara JungwirthNews2 Min ReadIn this real-world study, researchers concluded that high BMI need not be an automatic disqualifier for people who would otherwise consider LA-CAB/RPV. Antiretroviral TherapyVirologic Failure Risk Following “High Low-Level Viremia”Barbara JungwirthNews2 Min ReadA viral load that remained near 200 copies/mL emerged as a risk factor for eventual virologic failure among people on antiretroviral therapy in a Swiss study. Antiretroviral TherapyVirologic Failure Risk Following “High Low-Level Viremia”Barbara JungwirthNews2 Min ReadA viral load that remained near 200 copies/mL emerged as a risk factor for eventual virologic failure among people on antiretroviral therapy in a Swiss study. Adverse Events & ComorbiditiesConsider Menopausal Stage When Switching to Integrase InhibitorsBarbara JungwirthNews2 Min ReadTransitioning women with HIV to integrase inhibitors before (or more than three years after) menopause may minimize the impact on waist circumference and body mass. Adverse Events & ComorbiditiesConsider Menopausal Stage When Switching to Integrase InhibitorsBarbara JungwirthNews2 Min ReadTransitioning women with HIV to integrase inhibitors before (or more than three years after) menopause may minimize the impact on waist circumference and body mass. Providing Quality HIV CareTop 10 HIV Clinical Developments of 2024David Alain Wohl, M.D.We break down major developments in HIV treatment, prevention, and policy—each of which will change our approach to HIV care throughout the year to come. Providing Quality HIV CareTop 10 HIV Clinical Developments of 2024David Alain Wohl, M.D.We break down major developments in HIV treatment, prevention, and policy—each of which will change our approach to HIV care throughout the year to come. Switching or Stopping HIV TreatmentInjectable HIV Therapy Switch Study Offers SurprisesDavid Alain Wohl, M.D.Commentary4 Min ReadFrom our annual Top 10 analysis: A clever design and unexpected findings make the CARES study worthy of a second look. Switching or Stopping HIV TreatmentInjectable HIV Therapy Switch Study Offers SurprisesDavid Alain Wohl, M.D.Commentary4 Min ReadFrom our annual Top 10 analysis: A clever design and unexpected findings make the CARES study worthy of a second look. Adverse Events & ComorbiditiesThinking Twice About Causes of Weight Gain on HIV TherapyDavid Alain Wohl, M.D.Commentary5 Min ReadFrom our annual Top 10 analysis: Studies continue to report diverse findings on weight gain with antiretroviral drugs. The PASO-DOBLE trial in particular was bit of a head-scratcher. Adverse Events & ComorbiditiesThinking Twice About Causes of Weight Gain on HIV TherapyDavid Alain Wohl, M.D.Commentary5 Min ReadFrom our annual Top 10 analysis: Studies continue to report diverse findings on weight gain with antiretroviral drugs. The PASO-DOBLE trial in particular was bit of a head-scratcher. Managing HIV Drug ResistanceWe Need to Start Paying Attention to Dolutegravir ResistanceDavid Alain Wohl, M.D.Commentary5 Min ReadFrom our annual Top 10 analysis: Available data remain limited, but a new report from the WHO serves as a warning that action is needed. Managing HIV Drug ResistanceWe Need to Start Paying Attention to Dolutegravir ResistanceDavid Alain Wohl, M.D.Commentary5 Min ReadFrom our annual Top 10 analysis: Available data remain limited, but a new report from the WHO serves as a warning that action is needed. HIV Treatments in DevelopmentOnce-a-Week Oral HIV Therapy May Be Nearing RealityDavid Alain Wohl, M.D.Commentary3 Min ReadFrom our annual Top 10 analysis: We’re still waiting for the perfect oral long-acting ART matchup, but a solid step forward for “long-ish acting” ART was made this year. HIV Treatments in DevelopmentOnce-a-Week Oral HIV Therapy May Be Nearing RealityDavid Alain Wohl, M.D.Commentary3 Min ReadFrom our annual Top 10 analysis: We’re still waiting for the perfect oral long-acting ART matchup, but a solid step forward for “long-ish acting” ART was made this year.
